(¹²⁴I)-PUH71 | 1352930-11-0

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: (¹²⁴I)-PUH71
• 英文别名: 6-Amino-8-((6-(iodo-124I)-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-9H-purine-9-propanamine；8-[(6-(124I)iodanyl-1,3-benzodioxol-5-yl)sulfanyl]-9-[3-(propan-2-ylamino)propyl]purin-6-amine
• CAS: 1352930-11-0
• 化学式: C₁₈H₂₁IN₆O₂S
• 分子量: 509.47
• InChiKey: SUPVGFZUWFMATN-JVYRTNJDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  125
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  tert-butyl N-[3-[6-amino-8-[(6-(124I)iodanyl-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]propyl]-N-propan-2-ylcarbamate 在 盐酸 、 DL-methionine methyl ester 作用下， 以 甲醇 、 水 为溶剂， 反应 0.5h， 生成 (¹²⁴I)-PUH71
  参考文献：
  名称：

  WO2016/44629

  摘要：

  公开号：

文献信息

• HSP90-TARGETED CARDIAC IMAGING AND THERAPY
  申请人：MEMORIAL SLOAN-KETTERING CANCER CENTER

  公开号：US20160015837A1

  公开（公告）日：2016-01-21

  The present invention provides new methods for cardiac imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of cardiovascular diseases, conditions, or disorders. In some embodiments, the present invention provides a method for the treatment or prevention of cardiovascular diseases, conditions, or disorders. In some embodiments, the present invention provides methods for monitoring the effect of cancer treatment on the heart, and/or methods for monitoring a cancer treatment regimen. In some embodiments, the present invention provides a method for selecting subjects for a test or treatment. In some embodiments, the present invention provides a method for determining the dosage of a drug. In some embodiments, the present invention provides methods for determining the risk of a cardiovascular disease, for assessing risk of a cardiovascular disease, and/or for determining the risk of heart attack.

  本发明提供了心脏成像的新方法及相关的医疗应用。在某些实施例中，本发明提供了一种用于诊断心血管疾病、症状或障碍的方法。在某些实施例中，本发明提供了一种用于治疗或预防心血管疾病、症状或障碍的方法。在某些实施例中，本发明提供了用于监测癌症治疗对心脏的影响的方法，和/或用于监测癌症治疗方案的方法。在某些实施例中，本发明提供了一种用于选择测试对象或治疗的方法。在某些实施例中，本发明提供了一种确定药物剂量的方法。在某些实施例中，本发明提供了用于确定心血管疾病风险、评估心血管疾病风险和/或确定心脏病发风险的方法。
• USES OF LABELED HSP90 INHIBITORS
  申请人：Chiosis Gabriela

  公开号：US20140242602A1

  公开（公告）日：2014-08-28

  The disclosure provides evidence that the abundance of this particular “oncogenic HSP90” species, which is not dictated by HSP90 expression alone, predicts for sensitivity to HSP90 inhibition therapy, and thus is a biomarker for HSP90 therapy. The disclosure also provides evidence that identifying and measuring the abundance of this oncogenic HSP90 species in tumors predicts of response to HSP90 therapy. “Oncogenic HSP90” is defined herein as the HSP90 fraction that represents a cell stress specific form of chaperone complex, that is expanded and constitutively maintained in the tumor cell context, and that may execute functions necessary to maintain the malignant phenotype. Such roles are not only to regulate the folding of overexpressed (i.e. HER2), mutated (i.e. mB-Raf) or chimeric proteins (i.e. Bcr-Abl), but also to facilitate scaffolding and complex formation of molecules involved in aberrantly activated signaling complexes (i.e. STATS, BCL6).
• METHODS AND REAGENTS FOR RADIOLABELING
  申请人：Memorial Sloan-Kettering Cancer Center

  公开号：US20170029426A1

  公开（公告）日：2017-02-02

  The present invention provides methods for radiolabeling compounds useful as Hsp90 inhibitors. The present invention also provides intermediates useful in such methods, and compositions of radiolabeled compounds. The present invention provides, among other things, novel methods for the synthesis of radiolabeled compounds. In certain embodiments, the present invention provides compounds of formula I.
• HSP90-TARGETED INFLAMMATION AND INFECTION IMAGING AND THERAPY
  申请人：Memorial Sloan Kettering Cancer Center

  公开号：US20170304470A1

  公开（公告）日：2017-10-26

  The present invention provides new methods for inflammation and infection imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of inflammation and/or infection. In some embodiments, the present invention provides a method for the treatment or prevention of inflammation and/or infection. In some embodiments, the present invention provides methods for monitoring the effect of inflammation and/or infection treatment, and/or methods for monitoring an inflammation and/or infection treatment regimen. In some embodiments, the present invention provides a method for selecting subjects for an inflammation and/or infection treatment. In some embodiments, the present invention provides a method for determining the dosage of a drug for the treatment of inflammation and/or infection.
• US9555137B2
  申请人：——

  公开号：US9555137B2

  公开（公告）日：2017-01-31